Dr. Pierluigi Porcu, chief of Hematology and Cellular Therapy at the UK Markey Cancer Center, discusses what cellular therapy is, how it's transforming care for patients and what it can allow for going forward in cancer treatment.
Selected Podcast
Cellular Therapy at UK Markey Cancer Center
Pierluigi Porcu, MD
Pierluigi Porcu, MD is Chief, Hematoloy and Cellular Therapy at UK Markey Cancer Center.
Cellular Therapy at UK Markey Cancer Center
Scott Webb (Host): Welcome to UK HealthCast, a podcast from UK Healthcare. I'm Scott Webb. And today, we're going to learn about cellular therapy in cancer treatment from the Chief of Hematology and Cellular Therapy at the UK Markey Cancer Center, Dr. Pierluigi porcu.
Doctor, it's nice to have you here today. We're going to talk cellular therapy and what that means exactly. So, what is cellular therapy, and what makes it such a transformative area in oncology today?
Dr. Pierluigi Porcu: So, cellular therapy essentially is a form of therapy for diseases that span from cancer to autoimmune diseases, neurological diseases, and fundamentally is based on the fact that we're using human live cells for our treatment goal.
These cells, most of the times, are taken from the patient themselves, so they are so-called autologous cells. They are modified very often in a variety of different ways, and then they are infused back into the patient where, first, they grow, so they expand—so, these are live medicines that grow into the patients over a period of several weeks. And they find their target, whether it's a cancer cell or it is the cells that are triggering some of the autoimmune responses, and they target them, and they clear them. And the effect is durable because these cells that are infused back, they tend to stay in the body for an extended period of time, sometimes years.
Host: Okay. Yeah, it's very interesting and wondering maybe how the new cellular therapies help patients whose cancers have not responded to existing treatments.
Dr. Pierluigi Porcu: Yeah, it's just like for any therapy with the development of cell therapy, for example, something called CAR T cells, which was the first really type of engineered cell that was developed. Initially, those treatments were reserved for patients who had failed most of their standard of care therapies, and they had no other option, or they had lost hope, and their cancer was not responding. And that's where the value of this therapy really proved itself by producing responses that, you know, candidly were really completely unexpected in giving hope to patients.
Just like for any other therapy, as we learn more about the safety, right, and the specifics of how these cells really persist in the body and they evolve. And once safety and efficacy is demonstrated, then these therapy are moved back upfront because there may be patients with cancers that are difficult to treat from the very beginning, not necessarily after having failed, you know, multiple different treatments.
Host: Sure.
Dr. Pierluigi Porcu: That's what happened over the past, you know, 10 to 15 years, and those therapies have been moved up.
Host: Yeah, I can remember doing podcasts on CAR T cell and immunotherapy, and now add cellular therapy to this. You know, it makes me wonder, you know, when we think about the just sort of understanding, if you will, immune cell development and dysfunction, why it's so important for folks like yourself to create better cancer treatments.
Dr. Pierluigi Porcu: Yeah. One of the interesting things about cell therapy is the fact that it really sort of uses a mechanism to fight disease, cancer in particular, that is completely different from what the conventional chemotherapy. And, you know, cancers are smart. They tend to develop resistance to the treatments that they are exposed to. And this gives us the opportunity to attack the cancer from a completely different angle. So, this is really kind of the advantage and the game-changer effect that these therapies have.
Now, cell therapy evolved from a fairly old type of treatment that is what used to be called the bone marrow transplantation, now it's called stem cell therapy. And that was a relatively primitive, I would say, way of actually doing cell therapy. It was working, but it was nonspecific. The game-changer really was the fact that now we're developing personalized therapies for the specific patient that we have, that we see in the clinic. And patients get their specialized, specific, personalized treatment for them. That's really sort of the revolution that cell therapy has brought.
Host: Yeah. Yeah, as you say personalized, it made me think, you know, maybe what message you'd want to share with patients, families, communities across Kentucky about the future of cancer care.
Dr. Pierluigi Porcu: Absolutely. I mean, I think that one of the things that we have learned and slowly made progress on is the fact that every patient is different, every cancer is different. And therefore, sort of, you know, catch-all, fits-all kind of solutions, even though was the only thing that was available many, many years ago, are really not the best way to go. And one is because they often are not effective, and the other is that they often cause significant amount of, you know, side effects.
And so, the personalized approach here is the fact that, number one, we're using the patient-owned cells to really sort of build kind of the strategy for treatment and build a product that is going to be reinfused. And because the mechanism is different, I think we have a better chance of this therapy working.
In the course of that, that's also part of the scientific revolution that cell therapy has produced. In the course of that, we're learning a lot about the patient's own specific immune system, because as I said, every patient is different. Some patients are younger, some patients are older, some patients are more ill than others.
And when we take their cells and we train them to actually recognize the cancer, we have learned that not every patient is producing a product that is equally efficient. So, some patients, it will be more challenging for them and for us to produce a cell therapy product that is effective for them, right?
And we're learning, you know, what is driving those differences. And now, more importantly, we're learning how to modify those differences, so that both in vivo, so both, you know, in the patient himself or herself, as we prepare them to get the collection of the cells, but also in vitro, so in other words, in the laboratory, how to actually can modify those cells and make them smarter, make them more powerful, expand better, for example, and survive longer. So, all those things are things that we have learned from the very early days of cell therapy.
Host: Yeah. Doing a lot of head shaking over here. It's just really amazing. As you say, you know, cancer cells are smart. We need to outsmart them and train our cells and put them back into bodies. It's pretty amazing. But, Doctor, you know, I mentioned earlier, you know, immunotherapy, CAR T-cell, we're talking cellular therapy. I'm sure a lot of folks are just wondering, okay, but what does all that mean, right? How would you explain these treatments in, let's call it, everyday language?
Dr. Pierluigi Porcu: Of course. There are two ways of approaching that explanation. One is kind of the medical side of it, so the scientific side of it, explaining which kind of cells we're taking, how we're treating them, and, you know, how we are modifying them and so on.
The other is the practical side, which is what, you know, for the patient themselves, what actually happens, right? They come to the clinic. So, here's kind of a sequence of events that really, you know, patients who undergo this therapy have to be aware of how it's actually impacting their lives.
The patients have to be seen and, you know, their cancer has to be characterized in a very careful way. So, very often, that requires making sure that the pathology and the biopsies are accurate, the diagnosis is correct, and that, you know, there are all the different targets that the cell therapy requires are actually present. And this is done fairly routinely, so this is not in any way experimental.
And then, there is actually the logistics of, you know, the patients have to come in, they have to receive some therapy to prepare them for the collection of the cells. And then, they have to spend a day in something called the apheresis section in the apheresis lab, having the cells collected. Then, after that, they can go home. Cells typically take about two to three weeks to be manufactured. And then, they come back two to three weeks later, and they receive the cells in the office. So typically, this is a kind of outpatient ambulatory infusion. We keep ready, of course, and often we have to admit the patient to the hospital because for the initial monitoring, because these therapies tend to cause a lot of inflammation because that's the way they work.
So, inflammation is just kind of a byproduct of what we're asking the cells to do. And inflammation can cause fevers, can cause change in your blood pressure. And so, all of those things need to be monitored. We have very specific protocols to deal with that, but that requires quite a bit of time on the part of the patient as well.
So, it's a fairly engaging type of initial involvement. However, the beauty of cell therapy is that unlike most other cancer therapies that you need to come back off and on, off and on for multiple infusions, it only happens once. So, this is all given once.
Host: Right. It seems to me, Doctor, you know, we don't get where we are, we don't get to have conversations like this without the clinical trial. So, just wondering, you know, what opportunities do you see, you know, to expand the clinical trials at the UK Markey Cancer Center, and how maybe folks could get involved?
Dr. Pierluigi Porcu: Yeah. So, that's actually a fantastic question, because one thing that often is not emphasized enough is the fact that all these wonderful therapies that we have in the clinic, standard of care available to everybody who's eligible for it, these therapies were developed and are here now because there was clinical research that initially was invested in the development of those therapies. So, clinical trials are essentially the conduit, are the foundation for everything, every cancer therapy that we give today.
We are giving it because there were clinical trials that sort of helped with their development and established essentially the knowledge base, the safety information, and also kind of what we call the regulatory, you know, approvals from the FDA, for example, and other agencies, to make sure that they actually are used properly and for the right patients.
Host: Right. Yeah, this has been so educational. I feel like we could stay on for much longer, but in the interest of time and listeners' attention spans, what factors determine whether a patient can or may be considered for cellular therapy for a clinical trial?
Dr. Pierluigi Porcu: A lot of it has to do with the specific of their cancers. And I have to say that one of the big advantages here in Kentucky is the fact that, you know, we have a Markey Cancer Center that is an NCI-designated comprehensive cancer center, so it's the elite essentially of the cancer centers across the nation.
And therefore, clinical trials really are a primary mission for the cancer center serving essentially the population of Kentucky. So, Kentuckians across the state really have the opportunity to have access to therapies that no one else really has access outside of clinical trials, and we have these clinical trials here.
This includes things from, you know, very common cancers here in Kentucky, lung cancer, for example, gastrointestinal cancer, colon cancer, you name it. And then, of course, for all the blood cancers that have been, you know, in the front end of the development of these therapies. And so, the advantage is really the fact that people don't have to travel outside of the state to have access to these clinical trials. We can do them right here in Lexington at Markey.
Host: Never a good time to have cancer, Doctor, of course. But all the tools you have in your toolbox there and the clinical trials, lots of reason for optimism. I'm sure you share that. So, I appreciate your time and your expertise today. Thanks so much.
Dr. Pierluigi Porcu: Scott, thanks. It was great to be with you.
Host: And for more information, visit markey.uky.edu. And that wraps up another episode of UK HealthCast from UK Healthcare. Please remember to subscribe, rate, and review this podcast and all the other UK Healthcare podcasts. I'm Scott Webb. Stay well.